生物活性 | |||
---|---|---|---|
描述 | Belzutifan (PT2977), an orally bioavailable and selective inhibitor of HIF-2α, has an IC50 value of 9 nM. As a second-generation HIF-2α inhibitor, it offers enhanced potency and an optimized pharmacokinetic profile. Belzutifan holds promise as a treatment option for clear cell renal cell carcinoma (ccRCC)[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.61mL 0.52mL 0.26mL |
13.04mL 2.61mL 1.30mL |
26.09mL 5.22mL 2.61mL |
参考文献 |
---|